Teprotumumab for Thyroid-Associated Ophthalmopathy.

  title={Teprotumumab for Thyroid-Associated Ophthalmopathy.},
  author={Terry J. Smith and G J Kahaly and Daniel George Ezra and James Christian Fleming and Roger A. Dailey and Rosa Ana Tang and Gerald Harris and Alessandro Antonelli and Mario Salvi and Robert Alan Goldberg and James W. Gigantelli and Steven M. Couch and Erin M. Shriver and Brent R Hayek and Eric M. Hink and Richard M Woodward and Kathleen Gabriel and Guido Magni and Raymond S. Douglas},
  journal={The New England journal of medicine},
  volume={376 18},
BACKGROUND Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy. METHODS We conducted a multicenter, double-masked, randomized, placebo… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 124 times over the past 90 days. VIEW TWEETS
11 Citations
43 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 11 extracted citations


Publications referenced by this paper.
Showing 1-10 of 43 references

Interpretation and validity of changes in scores on the Graves’ ophthalmopathy The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY COLLEGE LONDON on December 8, 2017

  • CB Terwee, FW Dekker, MP Mourits
  • For personal use only. No other uses without…
  • 2017

Similar Papers

Loading similar papers…